⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149627 | 0.86 | — | — | |
| SCHEMBL24117892 | 0.83 | — | — | |
| SCHEMBL25143517 | 0.82 | — | — | |
| SCHEMBL20154592 | 0.80 | — | — | |
| SCHEMBL18294307 | 0.78 | — | — | |
| SCHEMBL14208073 | 0.78 | — | — | |
| SCHEMBL16249769 | 0.78 | — | — | |
| SCHEMBL21145973 | 0.78 | — | — | |
| SCHEMBL4546580 | 0.78 | — | — | |
| SCHEMBL12267691 | 0.78 | HRH3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |